Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes

Recruiting now · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Stem Cells, Type 1 Diabetes

In brief

Type 1 Diabetes is a chronic autoimmune disease. It results from autoimmune destruction of pancreatic Beta cells leading to absolute insulin insufficiency. The establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patients, especially in light of recent successes in producing glucose-sensitive insulin secreting cells and this will be the scope of this study. In the last decade, human clinical trials of introducing insulin producing stem cells from various origins were approved and conducted.

Key facts

Study ID

NCT06951074

Run by

Ain Shams University

People needed

20

Starts

2025-04-01

Expected to finish

2026-09-01

Last updated by the study team

2025-04-30

Who can join

Age: 15 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 1 diabetes

You may not qualify if…

• patients with other autoimmune diseases
• patients with micro or macro vascular complications
• patients with other chronic diseases

Where it is running

• Children Hospital Eldemerdash — Cairo, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.